Healthcare / Medical DevicesNasdaqCM
$0.66
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-13.3M · quality 82.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$9M
P/E
N/A
•EV/EBITDA
N/A
•ROE
1420.8%
↑Gross Margin
60.4%
↑Debt/Equity
-0.31
↓Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+7.4%
FCF CAGR
—
FCF margin
-100.9%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.4M · net income $-21.2M · FCF $-17.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $17.4M | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M | $11.4M |
| Net Income | $-21.2M | $-21.2M | $-11.1M | $-13.6M | $-23.8M | $-20.3M | $-12.1M | $-10.8M |
| EBITDA | $-18.6M | $-18.6M | $-10.6M | $-16.7M | $-24.4M | $-19.6M | $-11.3M | $-9.8M |
| EPS | -2.07 | -2.07 | -2.22 | -11.14 | -25.90 | -0.96 | — | — |
| Gross Margin | 60.4% | 60.4% | 60.0% | 59.9% | 62.5% | 74.6% | 79.7% | 76.0% |
| Operating Margin | -114.1% | -114.1% | -74.3% | -125.3% | -156.2% | -120.7% | -92.1% | -92.8% |
| Net Margin | -121.4% | -121.4% | -74.1% | -98.4% | -148.8% | -120.2% | -92.3% | -94.4% |
| Balance Sheet | ||||||||
| Debt/Equity | -0.31 | -0.31 | — | — | — | 0.05 | 0.03 | -1.26 |
| Cash Flow | ||||||||
| Free Cash Flow | $-17.6M | $-17.6M | $-13.3M | $-12.7M | $-20.5M | $-18.1M | $-5.8M | $-5.5M |
| Returns | ||||||||
| ROE | 1420.8% | 1420.8% | -140.0% | -3304.9% | -496.7% | -79.4% | -71.3% | 365.4% |
| Growth & Yield | ||||||||
| Revenue Growth | 16.0% | 16.0% | 8.9% | -13.9% | -5.1% | 29.2% | 14.7% | — |
| EPS Growth | 6.8% | 6.8% | 80.1% | 57.0% | -2597.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.